Association between BRAF V600E mutation and recurrence of papillary thyroid cancer

Mingzhao Xing, Ali S. Alzahrani, Kathryn A. Carson, Young Kee Shong, Tae Yong Kim, David Viola, Rossella Elisei, Bela Bendlová, Linwah Yip, Caterina Mian, Federica Vianello, R. Michael Tuttle, Eyal Robenshtok, James A. Fagin, Efisio Puxeddu, Laura Fugazzola, Agnieszka Czarniecka, Barbara Jarzab, Christine J. O'Neill, Mark S. SywakAlfred K. Lam, Garcilaso Riesco-Eizaguirre, Pilar Santisteban, Hirotaka Nakayama, Roderick Clifton-Bligh, Giovanni Tallini, Elizabeth H. Holt, Vlasta Sýkorová

Research output: Contribution to journalArticle

236 Citations (Scopus)

Abstract

Purpose: To investigate the prognostic value of BRAFV600E mutation for the recurrence of papillary thyroid cancer (PTC) Patients and Methods: This was a retrospective multicenter study of the relationship between BRAF V600E mutation and recurrence of PTC in 2,099 patients (1,615 women and 484 men), with a median age of 45 years (interquartile range [IQR], 34 to 58 years) and a median follow-up time of 36 months (IQR, 14 to 75 months) Results: The overall BRAF V600E mutation prevalence was 48.5% (1,017 of 2,099). PTC recurrence occurred in 20.9% (213 of 1,017) of BRAFV600E mutation-positive and 11.6% (125 of 1,082) of BRAFV600E mutation-negative patients. Recurrence rates were 47.71 (95% CI, 41.72 to 54.57) versus 26.03 (95% CI, 21.85 to 31.02) per 1,000 person-years in BRAF mutation-positive versus - Negative patients (P

Original languageEnglish
Pages (from-to)42-50
Number of pages9
JournalJournal of Clinical Oncology
Volume33
Issue number1
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Recurrence
Mutation
Multicenter Studies
Papillary Thyroid cancer
Retrospective Studies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Xing, M., Alzahrani, A. S., Carson, K. A., Shong, Y. K., Kim, T. Y., Viola, D., ... Sýkorová, V. (2015). Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. Journal of Clinical Oncology, 33(1), 42-50. https://doi.org/10.1200/JCO.2014.56.8253

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. / Xing, Mingzhao; Alzahrani, Ali S.; Carson, Kathryn A.; Shong, Young Kee; Kim, Tae Yong; Viola, David; Elisei, Rossella; Bendlová, Bela; Yip, Linwah; Mian, Caterina; Vianello, Federica; Tuttle, R. Michael; Robenshtok, Eyal; Fagin, James A.; Puxeddu, Efisio; Fugazzola, Laura; Czarniecka, Agnieszka; Jarzab, Barbara; O'Neill, Christine J.; Sywak, Mark S.; Lam, Alfred K.; Riesco-Eizaguirre, Garcilaso; Santisteban, Pilar; Nakayama, Hirotaka; Clifton-Bligh, Roderick; Tallini, Giovanni; Holt, Elizabeth H.; Sýkorová, Vlasta.

In: Journal of Clinical Oncology, Vol. 33, No. 1, 01.01.2015, p. 42-50.

Research output: Contribution to journalArticle

Xing, M, Alzahrani, AS, Carson, KA, Shong, YK, Kim, TY, Viola, D, Elisei, R, Bendlová, B, Yip, L, Mian, C, Vianello, F, Tuttle, RM, Robenshtok, E, Fagin, JA, Puxeddu, E, Fugazzola, L, Czarniecka, A, Jarzab, B, O'Neill, CJ, Sywak, MS, Lam, AK, Riesco-Eizaguirre, G, Santisteban, P, Nakayama, H, Clifton-Bligh, R, Tallini, G, Holt, EH & Sýkorová, V 2015, 'Association between BRAF V600E mutation and recurrence of papillary thyroid cancer', Journal of Clinical Oncology, vol. 33, no. 1, pp. 42-50. https://doi.org/10.1200/JCO.2014.56.8253
Xing, Mingzhao ; Alzahrani, Ali S. ; Carson, Kathryn A. ; Shong, Young Kee ; Kim, Tae Yong ; Viola, David ; Elisei, Rossella ; Bendlová, Bela ; Yip, Linwah ; Mian, Caterina ; Vianello, Federica ; Tuttle, R. Michael ; Robenshtok, Eyal ; Fagin, James A. ; Puxeddu, Efisio ; Fugazzola, Laura ; Czarniecka, Agnieszka ; Jarzab, Barbara ; O'Neill, Christine J. ; Sywak, Mark S. ; Lam, Alfred K. ; Riesco-Eizaguirre, Garcilaso ; Santisteban, Pilar ; Nakayama, Hirotaka ; Clifton-Bligh, Roderick ; Tallini, Giovanni ; Holt, Elizabeth H. ; Sýkorová, Vlasta. / Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. In: Journal of Clinical Oncology. 2015 ; Vol. 33, No. 1. pp. 42-50.
@article{2f412f70674548699fbbb2f2a46dfaeb,
title = "Association between BRAF V600E mutation and recurrence of papillary thyroid cancer",
abstract = "Purpose: To investigate the prognostic value of BRAFV600E mutation for the recurrence of papillary thyroid cancer (PTC) Patients and Methods: This was a retrospective multicenter study of the relationship between BRAF V600E mutation and recurrence of PTC in 2,099 patients (1,615 women and 484 men), with a median age of 45 years (interquartile range [IQR], 34 to 58 years) and a median follow-up time of 36 months (IQR, 14 to 75 months) Results: The overall BRAF V600E mutation prevalence was 48.5{\%} (1,017 of 2,099). PTC recurrence occurred in 20.9{\%} (213 of 1,017) of BRAFV600E mutation-positive and 11.6{\%} (125 of 1,082) of BRAFV600E mutation-negative patients. Recurrence rates were 47.71 (95{\%} CI, 41.72 to 54.57) versus 26.03 (95{\%} CI, 21.85 to 31.02) per 1,000 person-years in BRAF mutation-positive versus - Negative patients (P",
author = "Mingzhao Xing and Alzahrani, {Ali S.} and Carson, {Kathryn A.} and Shong, {Young Kee} and Kim, {Tae Yong} and David Viola and Rossella Elisei and Bela Bendlov{\'a} and Linwah Yip and Caterina Mian and Federica Vianello and Tuttle, {R. Michael} and Eyal Robenshtok and Fagin, {James A.} and Efisio Puxeddu and Laura Fugazzola and Agnieszka Czarniecka and Barbara Jarzab and O'Neill, {Christine J.} and Sywak, {Mark S.} and Lam, {Alfred K.} and Garcilaso Riesco-Eizaguirre and Pilar Santisteban and Hirotaka Nakayama and Roderick Clifton-Bligh and Giovanni Tallini and Holt, {Elizabeth H.} and Vlasta S{\'y}korov{\'a}",
year = "2015",
month = "1",
day = "1",
doi = "10.1200/JCO.2014.56.8253",
language = "English",
volume = "33",
pages = "42--50",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - Association between BRAF V600E mutation and recurrence of papillary thyroid cancer

AU - Xing, Mingzhao

AU - Alzahrani, Ali S.

AU - Carson, Kathryn A.

AU - Shong, Young Kee

AU - Kim, Tae Yong

AU - Viola, David

AU - Elisei, Rossella

AU - Bendlová, Bela

AU - Yip, Linwah

AU - Mian, Caterina

AU - Vianello, Federica

AU - Tuttle, R. Michael

AU - Robenshtok, Eyal

AU - Fagin, James A.

AU - Puxeddu, Efisio

AU - Fugazzola, Laura

AU - Czarniecka, Agnieszka

AU - Jarzab, Barbara

AU - O'Neill, Christine J.

AU - Sywak, Mark S.

AU - Lam, Alfred K.

AU - Riesco-Eizaguirre, Garcilaso

AU - Santisteban, Pilar

AU - Nakayama, Hirotaka

AU - Clifton-Bligh, Roderick

AU - Tallini, Giovanni

AU - Holt, Elizabeth H.

AU - Sýkorová, Vlasta

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Purpose: To investigate the prognostic value of BRAFV600E mutation for the recurrence of papillary thyroid cancer (PTC) Patients and Methods: This was a retrospective multicenter study of the relationship between BRAF V600E mutation and recurrence of PTC in 2,099 patients (1,615 women and 484 men), with a median age of 45 years (interquartile range [IQR], 34 to 58 years) and a median follow-up time of 36 months (IQR, 14 to 75 months) Results: The overall BRAF V600E mutation prevalence was 48.5% (1,017 of 2,099). PTC recurrence occurred in 20.9% (213 of 1,017) of BRAFV600E mutation-positive and 11.6% (125 of 1,082) of BRAFV600E mutation-negative patients. Recurrence rates were 47.71 (95% CI, 41.72 to 54.57) versus 26.03 (95% CI, 21.85 to 31.02) per 1,000 person-years in BRAF mutation-positive versus - Negative patients (P

AB - Purpose: To investigate the prognostic value of BRAFV600E mutation for the recurrence of papillary thyroid cancer (PTC) Patients and Methods: This was a retrospective multicenter study of the relationship between BRAF V600E mutation and recurrence of PTC in 2,099 patients (1,615 women and 484 men), with a median age of 45 years (interquartile range [IQR], 34 to 58 years) and a median follow-up time of 36 months (IQR, 14 to 75 months) Results: The overall BRAF V600E mutation prevalence was 48.5% (1,017 of 2,099). PTC recurrence occurred in 20.9% (213 of 1,017) of BRAFV600E mutation-positive and 11.6% (125 of 1,082) of BRAFV600E mutation-negative patients. Recurrence rates were 47.71 (95% CI, 41.72 to 54.57) versus 26.03 (95% CI, 21.85 to 31.02) per 1,000 person-years in BRAF mutation-positive versus - Negative patients (P

UR - http://www.scopus.com/inward/record.url?scp=84920593838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920593838&partnerID=8YFLogxK

U2 - 10.1200/JCO.2014.56.8253

DO - 10.1200/JCO.2014.56.8253

M3 - Article

C2 - 25332244

AN - SCOPUS:84920593838

VL - 33

SP - 42

EP - 50

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -